Novo Nordisk Net Profit Margin 2010-2023 | NVO

Current and historical net profit margin for Novo Nordisk (NVO) from 2010 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue. Novo Nordisk net profit margin for the three months ending December 31, 2023 was .
Novo Nordisk Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2023-12-31 $33.72B $12.15B 36.03%
2023-09-30 $30.85B $10.84B 35.14%
2023-06-30 $28.44B $9.51B 33.43%
2023-03-31 $26.41B $8.57B 32.47%
2022-12-31 $25.06B $7.86B 31.38%
2022-09-30 $24.32B $7.66B 31.50%
2022-06-30 $23.81B $7.63B 32.07%
2022-03-31 $23.26B $7.70B 33.08%
2021-12-31 $22.40B $7.60B 33.92%
2021-09-30 $21.64B $7.45B 34.40%
2021-06-30 $20.85B $7.14B 34.25%
2021-03-31 $19.93B $6.74B 33.85%
2020-12-31 $19.45B $6.46B 33.19%
2020-09-30 $19.09B $6.23B 32.63%
2020-06-30 $18.74B $6.13B 32.70%
2020-03-31 $18.84B $6.01B 31.89%
2019-12-31 $18.29B $5.84B 31.92%
2019-09-30 $17.43B $5.62B 32.25%
2019-06-30 $17.25B $5.51B 31.96%
2019-03-31 $17.11B $5.72B 33.44%
2018-12-31 $17.10B $5.91B 34.55%
2018-09-30 $17.61B $6.16B 34.98%
2018-06-30 $17.49B $6.30B 36.00%
2018-03-31 $17.33B $6.11B 35.26%
2017-12-31 $16.97B $5.79B 34.14%
2017-09-30 $16.81B $5.73B 34.07%
2017-06-30 $16.73B $5.65B 33.78%
2017-03-31 $16.67B $5.69B 34.16%
2016-12-31 $16.61B $5.64B 33.92%
2016-09-30 $16.56B $5.59B 33.73%
2016-06-30 $16.43B $5.37B 32.67%
2016-03-31 $16.26B $5.09B 31.28%
2015-12-31 $16.06B $5.19B 32.30%
2015-09-30 $15.99B $5.08B 31.75%
2015-06-30 $15.95B $4.98B 31.24%
2015-03-31 $15.92B $5.03B 31.62%
2014-12-31 $15.83B $4.72B 29.82%
2014-09-30 $15.63B $4.74B 30.30%
2014-06-30 $15.31B $4.72B 30.81%
2014-03-31 $15.08B $4.61B 30.58%
2013-12-31 $14.89B $4.49B 30.13%
2013-09-30 $14.58B $4.38B 30.06%
2013-06-30 $14.27B $4.20B 29.40%
2013-03-31 $13.89B $3.94B 28.37%
2012-12-31 $13.48B $3.70B 27.47%
2012-09-30 $13.04B $3.53B 27.07%
2012-06-30 $12.80B $3.36B 26.28%
2012-03-31 $12.52B $3.24B 25.85%
2011-12-31 $12.27B $3.16B 25.77%
2011-09-30 $12.04B $3.06B 25.42%
2011-06-30 $11.85B $2.94B 24.83%
2011-03-31 $11.48B $2.77B 24.13%
2010-12-31 $11.06B $2.62B 23.70%
2010-09-30 $10.66B $2.35B 22.05%
2010-06-30 $10.24B $2.23B 21.78%
2010-03-31 $9.90B $2.15B 21.72%
2009-12-31 $9.67B $2.03B 21.03%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $591.861B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AbbVie (ABBV) United States $293.876B 15.18
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Novartis AG (NVS) Switzerland $209.653B 14.87
Pfizer (PFE) United States $162.291B 20.17
Sanofi (SNY) $123.116B 11.62
Innoviva (INVA) United States $0.998B 7.01